Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results provided evidence for the potential applications of RNA interference of the targeted COX‑2 gene in gene therapy for the treatment of breast cancer.
|
25323004 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have proved that it can inhibit the proliferation of breast cancer cell lines and upregulate some cytokines such as cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF).
|
27323060 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This finding may be helpful to elucidate the mechanisms of selective COX-2 inhibitor action in EMT modulation in breast cancer.
|
25520137 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The second step was a case-control study with 318 patients and 273 controls designed to evaluate PTGS2 genotype- or haplotype-associated risk of breast cancer.
|
21059239 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, ST3Gal III expression modulated the protein expression of invasion-related molecules, including β1 integrin, matrix metalloproteinase (MMP)-2, MMP-9 and cyclooxygenase-2, which may account for the mechanism involved in the effects of ST3Gal III on breast cancer invasiveness.
|
27779707 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of COX-2 has been found in a majority of breast carcinomas, and has also been associated with increased severity and the development of the metastasis.
|
29587668 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings of the primary role of COX-2 and the COX-2-dependent role of HER-2, if any, in VEGF-C up-regulation and lymphangiogenesis suggest that COX-2 inhibitors may abrogate lymphatic metastasis in breast cancer irrespective of HER-2 status.
|
20608938 |
2010 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TGFbeta signaling has been reported to be inhibited by COX-2, and these molecules are highly differentially expressed in individuals at high risk of developing breast cancer.
|
19241157 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The rs5275 polymorphism in the 3' untranslated region of the PTGS2 gene was associated with a decrease in breast cancer risk.
|
17214885 |
2007 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>), one of the terminal products of cyclooxygenase-2-catalized arachidonic acid metabolism, has been shown to stimulate breast cancer cell proliferation and migration through Akt activation, but the underlying mechanisms remain poorly understood.
|
29550515 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was done in order to develop therapeutic agents for the treatment of breast cancer with improved Cycloxygenase-2 (COX-2) selectivity.
|
28486908 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CPEB2 (isoform A) expression was inversely correlated with COX-2 or the above microRNAs in COX-2-divergent breast cancer cell lines.
|
31185986 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, vascular channels were analyzed in surgically resected human breast cancer specimens that expressed varying levels of COX-2.
|
17156488 |
2006 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to elucidate the factors contributing to intratumoral PGE2 levels, we evaluated the expression of COX-2/PGE2 pathway members MRP4, the prostaglandin transporter PGT, 15-PGDH (PGE2 metabolism), the prostaglandin E receptor EP4, COX-1, and COX-2 in normal, luminal, and basal breast cancer cell lines.
|
28029661 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also demonstrate that cigarette smoke induces the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 and reduces 15-hydroxyprostaglandin dehydrogenase, resulting in prostaglandin E<sub>2</sub> release in human breast cancer.
|
28618256 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
From this study we conclude that the expression of COX-2 was similar in the in situ and invasive components of the breast carcinomas.
|
21683430 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, RXR-selective retinoids that inhibit AP-1 activity and suppress COX-2 expression may be particularly promising drugs for breast cancer prevention.
|
15833882 |
2005 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) expression may be a driver of immunosuppression in breast cancer, but the mechanisms involved remain elusive.
|
31759380 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that concurrent use of glucocorticoids, ACE inhibitors, aspirin, NSAIDs, selective COX-2 inhibitors, digoxin, and opioids has little impact on breast cancer recurrence.
|
29202630 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we explored the clinical relevance of CacyBP and investigated the relationship between CacyBP and COX-2 in breast cancer.
|
20878073 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2-rs20417 CC genotype was significantly associated with increased risk of breast cancer when comparing to G allele [ORs were 1.231 (1.050-1.444) for CC vs. GG, P = 0.01, 1.223 (1.045-1.432) for CC vs. G carrier, P = 0.01].
|
25433948 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1.There are numerous investigations demonstrating that the cyclooxygenase-2 (COX-2) inhibitors might enhance the efficiency of anastrozole in breast cancer.
|
28906164 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 induction by heparanase in the progression of breast cancer.
|
16391819 |
2006 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A positive correlation was noted between miR-526b and COX-2 mRNA expression in COX-2 disparate breast cancer cell lines.
|
25733698 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results were partially duplicated with a human dermal LEC (HMVEC-dLyAd) and a COX-2 expressing human breast cancer cell line MDA-MB-231.
|
28056899 |
2017 |